Group plots new biotech building in MD

Alexandria Real Estate Equities has laid plans to build a four-story, 100,000-square-foot biotech lab on Maryland's I-270 corridor--an area that's already thick with developers. The group refused to say how much the project will costs but aims to have the building completed by the end of 2012. Report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.